Ada Girnita
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ada Girnita has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Benjamin Gebhard
Department of Oncology and Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
24 shared publications - Caitrin Crudden
Vrije Universiteit Amsterdam
24 shared publications - Dawei Song
Department of Oncology and Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
24 shared publications - George Adrian Calin
The University of Texas MD Anderson Cancer Center
24 shared publications - Iara Troccoli Drakensjo
Department of Oncology and Pathology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
24 shared publications - Leonard Girnita
Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
24 shared publications
Latest Publications
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 4 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin imbalance on IGF1R expression
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 4 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin imbalance on IGF1R expression
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Table S1. Cell lines used in this study.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Table S1. Cell lines used in this study.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin imbalance on response to dacarbazine (DTIC)
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin imbalance on response to dacarbazine (DTIC)
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin isoform imbalance on survival of patients with metastatic melanoma.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin isoform imbalance on survival of patients with metastatic melanoma.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 8 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin isoform imbalance on survival of patients with metastatic melanoma.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 8 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin isoform imbalance on survival of patients with metastatic melanoma.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 5 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Rescue-validation of β-arrestin imbalance effects on MDM2-dependent IGF1R expression.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 5 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Rescue-validation of β-arrestin imbalance effects on MDM2-dependent IGF1R expression.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin imbalance on MDM2 localization
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of β-arrestin imbalance on MDM2 localization
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Specificity of β-arrestin1/2 siRNA effectson MDM2 localization.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Specificity of β-arrestin1/2 siRNA effectson MDM2 localization.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 7 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of combination treatment on p53-activation in skin melanoma malignant phenotype in in vitro 3D models
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 7 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Effect of combination treatment on p53-activation in skin melanoma malignant phenotype in in vitro 3D models
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Table S2. Antibodies used in this study.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Competing engagement of β-arrestin isoforms balances IGF1R/p53 signaling and controls melanoma cell chemotherapeutic responsiveness
Table S2. Antibodies used in this study.